(primary solid tumor cohort)
This pipeline maps genes, with mutation or copy number alteration AND this alteration is highly correlated with mRNA expression, to pathways curated in the KEGG and BIOCARTA databases. It identifies pathways significantly enriched with these genes. The pipeline also identifies pathways significantly enriched with marker genes of each expression subtype of cancer.
genes with mutation: identified by the Mutation_Significance pipeline
genes with copy number alteration: identified by the CopyNumber_Gistic2 pipeline
correlation between copy number and mRNA expression: identified by the Correlate_CopyNumber_vs_mRNA pipeline
marker genes and expression subtypes: identified by the mRNAConsensusClustering pipeline
There are 120 genes with significant mutation (Q value <= 0.1) and 550 genes with significant copy number alteration (Q value <= 0.25). The identified marker genes (Q value <= 0.01 or within top 2000) are 2000 for subtype 1, 2000 for subtype 2, 2000 for subtype 3. Pathways significantly enriched with these genes (Q value <= 0.01) are identified :
0 pathways significantly enriched with genes with copy number alteration or mutation.
0 pathways significantly enriched with marker genes of gene expression subtype 1
1 pathways significantly enriched with marker genes of gene expression subtype 2
2 pathways significantly enriched with marker genes of gene expression subtype 3
Pathway | Nof Genes | Nof CNV_Mut | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_MTOR_PATHWAY | 23 | 6 | 3 | 0.0001 | 0.021 |
BIOCARTA_PYK2_PATHWAY | 29 | 6 | 2.8 | 0.0002 | 0.024 |
BIOCARTA_PROTEASOME_PATHWAY | 19 | 5 | 3 | 0.0003 | 0.024 |
BIOCARTA_IGF1MTOR_PATHWAY | 20 | 5 | 3 | 0.0003 | 0.024 |
KEGG_RIBOSOME | 87 | 10 | 1.9 | 0.0004 | 0.024 |
FKBP1A,RPS6,PTEN,EIF6,EIF4A2,PIK3CA
SRC,RAC1,MAP2K4,RAF1,PLCG1,CALM1
UBE3A,PSMA7,PSMB5,PSMA6,RPN2
RPS6,PTEN,EIF2S1,EIF2S2,PIK3CA
RPL36AL,RPS17,RPS15,RPL37,RPS27,RPL32,RPS20,RPS21,RPS24,RPS6
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_NO1_PATHWAY | 31 | 9 | 1.8 | 0.0008 | 0.052 |
BIOCARTA_IL2RB_PATHWAY | 38 | 11 | 1.7 | 0.0003 | 0.052 |
KEGG_AXON_GUIDANCE | 129 | 23 | 1 | 0.0006 | 0.052 |
BIOCARTA_GCR_PATHWAY | 20 | 6 | 1.8 | 0.0045 | 0.099 |
BIOCARTA_EIF4_PATHWAY | 24 | 7 | 1.7 | 0.0036 | 0.099 |
CAV1,PDE3B,AKT1,NOS3,PRKACB,FLT1,FLT4,CALM3,CALM2
E2F1,STAT5B,BCL2L1,AKT1,FOS,IL2RG,PIK3R1,SYK,PTPN6,SOCS1,MAPK1
PLXNA2,ROBO2,ROBO3,PLXNB1,CHP2,MAPK1,RND1,GNAI3,EPHB1,SEMA5B,KRAS,RAC2,SEMA6A,FES,CFL2,SRGAP3,SEMA4C,SEMA4B,ABLIM2,PPP3CA,NGEF,DPYSL2,FYN
AKT1,ADRB2,CALM3,NOS3,PIK3R1,CALM2
PDK2,AKT1,MAPK1,PDPK1,PABPC1,PIK3R1,GHR
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_PURINE_METABOLISM | 158 | 32 | 1.2 | 0 | 0.0019 |
BIOCARTA_AMI_PATHWAY | 20 | 7 | 2 | 0.0011 | 0.12 |
KEGG_SMALL_CELL_LUNG_CANCER | 84 | 17 | 1.2 | 0.0009 | 0.12 |
BIOCARTA_G1_PATHWAY | 28 | 8 | 1.7 | 0.0022 | 0.16 |
KEGG_FOCAL_ADHESION | 201 | 30 | 0.75 | 0.0024 | 0.16 |
ADCY5,PDE3B,PDE4D,POLR2J2,NME7,PDE5A,ADSS,ENPP3,PPAT,PDE6A,ADSSL1,AK7,PDE6H,PDE6G,PDE7A,GUK1,PDE11A,CANT1,NT5E,POLR1E,PDE10A,GMPR,PKM2,POLR2I,POLA2,AK3L1,PDE1A,PAPSS1,POLR3GL,POLR3A,AMPD3,PAICS
F10,COL4A6,PLG,PROC,FGA,FGB,ERAF
E2F1,CASP9,NOS2,PIK3CD,CYCS,SKP2,CDK6,CDK2,CCND1,PIAS2,LAMC1,PIK3R5,ITGA2,COL4A6,CDKN1B,ITGA6,LAMA5
E2F1,TGFB3,SMAD4,SKP2,CDK6,CDK2,CCND1,CDKN1B
PIK3CD,PPP1CA,LAMC1,PXN,LAMA5,PDPK1,FLNB,CCND1,COL3A1,COL6A2,THBS2,CAPN2,FYN,MYL7,MYL2,DOCK1,ITGA2,ITGA6,ITGA5,ITGA8,RAP1A,MYLK,PAK3,CRKL,TNC,IGF1R,PIK3R5,COL5A2,COL4A6,GRLF1
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_CELL_ADHESION_MOLECULES_CAMS | 134 | 29 | 1.4 | 0 | 0.0004 |
KEGG_ALLOGRAFT_REJECTION | 38 | 12 | 2 | 0 | 0.003 |
KEGG_TYPE_I_DIABETES_MELLITUS | 44 | 12 | 1.7 | 0.0001 | 0.012 |
KEGG_GRAFT_VERSUS_HOST_DISEASE | 42 | 11 | 1.8 | 0.0002 | 0.014 |
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION | 48 | 12 | 1.6 | 0.0003 | 0.018 |
HLA-F,HLA-DPA1,MADCAM1,HLA-DRA,GLG1,PVRL2,HLA-DOA,ITGA4,ITGA6,CLDN8,CD8A,CLDN3,CLDN6,SDC4,HLA-DMA,ICAM3,NRXN1,CD86,CD80,CNTN1,JAM2,CLDN19,CDH4,VCAM1,CD4,CD28,NLGN1,NLGN2,NLGN3
TNF,FASLG,HLA-DMA,HLA-DOA,CD28,GZMB,HLA-F,CD86,CD80,IL12A,HLA-DPA1,HLA-DRA
TNF,FASLG,HLA-DMA,HLA-DOA,CD28,GZMB,HLA-F,CD86,CD80,IL12A,HLA-DPA1,HLA-DRA
TNF,FASLG,HLA-DMA,HLA-DOA,CD28,GZMB,HLA-F,CD86,CD80,HLA-DPA1,HLA-DRA
ENC1,HLA-DMA,HLA-DOA,CD28,TNFRSF17,ITGA4,CD86,CD80,MADCAM1,HLA-DPA1,MAP3K14,HLA-DRA
Let genes with copy number alteration or mutation be query genes. Let marker genes of specific identified subtypes be query genes. The Enrichment is calculated as:
-
Enrichment = log2 (# of query genes in the pathway/# No of query genes) - log2 (# of genes in the pathway/# of human genes)
The statistical signficance of the pathways that are enriched with genes with copy number alteration or mutation, and the pathways that are enriched with markers genes of specific identified subtypes is measured by P value.
-
P value = Fisher exact P value
The Q value is for adjusting P value for multiple testing. A public available R package is used to calculate the Q value.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.